355 related articles for article (PubMed ID: 25707526)
1. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
Du YH; Guan CJ; Li LY; Gan P
Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
Liu X; Ma L; Li Z
J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
[TBL] [Abstract][Full Text] [Related]
6. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
Whitlock R; Leon SJ; Manacsa H; Askin N; Rigatto C; Fatoba ST; Farag YMK; Tangri N
Nephrol Dial Transplant; 2023 Oct; 38(11):2503-2516. PubMed ID: 37309038
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An J; Niu F; Sim JJ
Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
Tian ML; Shen Y; Sun ZL; Zha Y
Int Urol Nephrol; 2015 May; 47(5):815-22. PubMed ID: 25862237
[TBL] [Abstract][Full Text] [Related]
9. [Meta analysis of the efficacy and safety of combined treatment with ARB and ACEI on diabetic kidney disease].
Gu J; Han L; Liu Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):623-30. PubMed ID: 23828705
[TBL] [Abstract][Full Text] [Related]
10. Update on role of direct renin inhibitor in diabetic kidney disease.
Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
[TBL] [Abstract][Full Text] [Related]
11. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
13. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
St Peter WL; Odum LE; Whaley-Connell AT
Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments.
Tu X; Ye X; Xie C; Chen J; Wang F; Zhong S
Curr Vasc Pharmacol; 2015; 13(4):526-39. PubMed ID: 25360835
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis.
Lin YQ; Yu F; Chen HJ; Deng YR; Lin J; Xu Y; Zheng X; Zhang JW; Liu JF
Ren Fail; 2024 Dec; 46(2):2359033. PubMed ID: 38836372
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis.
Cheng J; Zhang X; Tian J; Li Q; Chen J
Int J Clin Pract; 2012 Oct; 66(10):917-23. PubMed ID: 22994326
[TBL] [Abstract][Full Text] [Related]
19. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
Titan SM; M Vieira J; Dominguez WV; Barros RT; Zatz R
Clin Nephrol; 2011 Oct; 76(4):273-83. PubMed ID: 21955862
[TBL] [Abstract][Full Text] [Related]
20. Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: a meta-analysis.
Luo Y; Yang SK; Zhou X; Wang M; Tang D; Liu FY; Sun L; Xiao L
Ren Fail; 2015 May; 37(4):614-34. PubMed ID: 25682973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
